Sensorion SA (ALSEN.PA)
- Previous Close
0.4000 - Open
0.4187 - Bid --
- Ask --
- Day's Range
0.4050 - 0.4550 - 52 Week Range
0.1544 - 0.9700 - Volume
439,696 - Avg. Volume
496,022 - Market Cap (intraday)
126.014M - Beta (5Y Monthly) 1.14
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0900 - Earnings Date Mar 14, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.50
Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. The company's product portfolio includes SENS-401 SSNHL, which has completed Phase 2b clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2a clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2a clinical which is an orally available small molecule protecting and preserving inner ear tissue from damage, responsible for hearing impairment. It is also developing OTOF-GT (SENS-501), a gene therapy development program that has completed Phase 1/2 clinical trial to restore hearing in people living with Otoferlin deficiency; and GJB2-GT, a gene therapy development program, which is in pre-clinical trial to restore hearing in people living with hearing loss due to mutations in the GJB2 gene. The company was incorporated in 2009 and is headquartered in Montpellier, France.
www.sensorion.comRecent News: ALSEN.PA
View More
Performance Overview: ALSEN.PA
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALSEN.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALSEN.PA
View MoreValuation Measures
Market Cap
120.21M
Enterprise Value
45.43M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.67
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.15%
Return on Equity (ttm)
-49.28%
Revenue (ttm)
6.65M
Net Income Avi to Common (ttm)
-25.97M
Diluted EPS (ttm)
-0.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
76.98M
Total Debt/Equity (mrq)
2.93%
Levered Free Cash Flow (ttm)
-15.12M